english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Proton pump inhibitors: avoid unjustified risks, and know how to "deprescribe"

It is better to be aware of the harms of prolonged use of proton pump inhibitors (drugs for gastrointestinal disorders), and to avoid prescribing or advising these drugs too readily.
1 July 2021

Food supplements: too readily authorised and sometimes dangerous

Several factors contribute to a major ongoing confusion between food supplements and medicinal products. Large numbers of safety signals increasingly indicate the need for caution, whereas the benefit of taking food supplements remains uncertain.
1 July 2021

Oral semaglutide (Rybelsus°): more uncertainty than with subcutaneous liraglutide

FEATURED REVIEW Semaglutide was first authorised in the European Union as a solution for weekly subcutaneous injections. It was authorised more recently in oral tablet form. How do Prescrire's editors rate this new product?
Full review (3 pages) available for download by subscribers.
1 June 2021

In the June issue of Prescrire International: Non-metastatic, castration-resistant prostate cancer

FREE DOWNLOAD Survival extended with the addition of apalutamide or enzalutamide.
Full text available for free download.
1 June 2021

Covid-19 drugs and vaccines: big money and winning alliances

 Editorial   The market for covid-19 drugs and vaccines is huge, involving billions of patients, with tens of billions of dollars potentially up for grabs. Business as usual? Not quite.
1 June 2021

Iodine during pregnancy: supplementation should not be systematic

Iodine-containing food supplements have no proven benefits for pregnant women, and can be dangerous for the unborn child.
1 June 2021

Oral cancer drugs: care provided in community pharmacies

Community pharmacists in France can offer, and claim payment for, structured pharmaceutical care for the growing number of patients taking oral cancer drugs.
1 June 2021

Memantine (Ebixa° and other brands): perception disorders

Memantine is a drug with psychotropic actions, misuse of which can become problematic, leading, in particular, to dissociative disorders which are not always effects being sought by the user.
1 June 2021

Pre-exposure prophylaxis for HIV (PrEP): reduction in risk of infection confirmed

For patients at high risk of infection by the HIV virus, evaluation has confirmed the efficacy of PrEP using a combination of emtricitabine + tenofovir disoproxil (Truvada° and other brands).
1 June 2021

Prescrire: independence and transparency, in the name of better patient care

No conflicts of interestThe independent French medical journal Prescrire is produced by healthcare professionals who strive to protect medical information and continuing education from the contradictory influences at play in the medico-pharmaceutical arena.
1 June 2021

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90